Breaking News
April 26, 2018 - Consuming large quantities of sugar during pregnancy can affect child’s cognition, shows study
April 26, 2018 - Researchers create new tool to measure patient uncertainty for predicting hospital readmissions
April 26, 2018 - FDA Alert: Lamictal (lamotrigine): Drug Safety Communication
April 26, 2018 - Massive single-cell survey of kidney cell types reveals new paths to disease
April 26, 2018 - Cognitive behavioral therapy can help children with autism manage emotional challenges
April 26, 2018 - CU Anschutz Medical Campus receives NIH grant to speed up discovery of new treatments
April 26, 2018 - Researchers discover significant distortions in leading genetics study method
April 26, 2018 - New combination therapy could improve survival in children with high-risk neuroblastoma
April 26, 2018 - Scientists clarify casual role of oxidative stress in metabolically abnormal and healthy obesities
April 26, 2018 - Home-based exercise program found ineffective for patients with peripheral artery disease
April 26, 2018 - Choroidal Thickness Changes in Patients With Untreated DM
April 26, 2018 - Medical chemists discover peptic ulcer treatment metallodrug effective in ‘taming’ superbugs
April 26, 2018 - UB researchers build 3D-printed, drug-filled dentures to fight against infections
April 26, 2018 - Researchers find role of iron storage gene in slowing down prostate cancer growth
April 26, 2018 - Study suggests link between regular mid-day naps and neurocognitive function in teens
April 26, 2018 - Researchers gain ground-breaking insights into how inflammatory diseases work
April 26, 2018 - Injured U.S. Vet Receives World’s First Penis/Scrotum Transplant
April 26, 2018 - Researchers find existing drug effective at preventing onset of type 1 diabetes
April 26, 2018 - MGH researchers identify risk factors for drug overdose in youth with substance use disorders
April 26, 2018 - Researchers develop new vaccine to help people overcome bath salts abuse
April 26, 2018 - Genetic signature predicts diabetes diagnosis
April 26, 2018 - Study shows link between restless legs syndrome symptoms and brain structure
April 26, 2018 - MU researchers use new techniques to fight against diabetic retinopathy
April 26, 2018 - AAE’s new practice statements aim at improving patient care
April 26, 2018 - Expression of long non-coding RNAs can result in high levels of specific proteins involved in cancer
April 26, 2018 - FDA re-examining safety of new drug approved for Parkinson’s disease psychosis
April 26, 2018 - Unanimous Positive Result of FDA Advisory Committee Meeting for First Plant-Based Pharmaceutical Cannabidiol Treatment for Seizures in Patients with Two Rare, Severe Forms of Epilepsy
April 26, 2018 - Bacteria boost antifungal drug resistance in severe childhood tooth decay
April 26, 2018 - New study affirms bedtime habits of Americans
April 26, 2018 - Hospital patients are more interested in tracking their health data, research shows
April 26, 2018 - Study shows gene variations associated with malaria risk
April 26, 2018 - Inhealthcare teams up with MSKassist to combat problems related to obesity and aging
April 26, 2018 - Caffeine during pregnancy – babies 66 percent more likely to become overweight
April 26, 2018 - FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
April 26, 2018 - Pricey dental implants often best but insurance rarely pays
April 26, 2018 - Advion’s Peak Express software now available with the expression compact mass spectrometer
April 25, 2018 - Researchers find link between pneumonia in older people and PPI prescriptions
April 25, 2018 - Alcohol damages microbiome in the mouth
April 25, 2018 - Regular soaking in hot tub improves health outlook in obese women with PCOS
April 25, 2018 - FDA Alert: Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers
April 25, 2018 - Sunshine could hold clues on the timing for a severe form of heart attack, study says
April 25, 2018 - Sartorius Stedim Biotech launches mini bioreactor vessel for ambr 250 high throughput system
April 25, 2018 - Biofeedback-assisted relaxation may help children during medical procedures
April 25, 2018 - Key signaling protein in Huntington’s disease found to have deleterious effects on heart function, shows study
April 25, 2018 - Celecoxib Lowers Opioid Use Post Head & Neck Cancer Surgery
April 25, 2018 - New ‘brain health index’ can predict how well patients will do after stroke
April 25, 2018 - Positive interventions in sepsis management raise key questions about E. coli reduction targets
April 25, 2018 - Scientists identify new DNA structure within living human cells
April 25, 2018 - E. coli’s toxin-antitoxin system inhibits bacterial growth
April 25, 2018 - Researchers uncover reason why exercise may be beneficial for the heart
April 25, 2018 - Researcher presents case study of asymptomatic patient with severe mitral regurgitation
April 25, 2018 - Use ‘Proper Form’ When Practicing Yoga
April 25, 2018 - Study reports possible novel method for stopping untreatable pediatric brain cancers
April 25, 2018 - Visually guided walking paves way for better treatment for mobility impairments
April 25, 2018 - Researchers identify novel pathway in development of AML with poor prognosis
April 25, 2018 - Cardiovascular disease may only be a matter of time for people with healthy obesity
April 25, 2018 - Girls with type 2 diabetes have high frequency of menstrual irregularities
April 25, 2018 - Study explains why intense exercise curbs appetite
April 25, 2018 - Experimental drug for rheumatoid arthritis prevents side effect of stem cell transplants
April 25, 2018 - Why are Antibiotics Overprescribed for Meningitis Treatment?
April 25, 2018 - Consuming protein supplements with meals, rather than between meals, may promote weight control
April 25, 2018 - Seeing prostate cancer in a new light
April 25, 2018 - Jacobs Medical Center recognized with Baby Friendly Designation for efforts in mother-baby bonding
April 25, 2018 - Gene related to high fatality could be used as biomarker in patients with P. aeruginosa infection
April 25, 2018 - Study shows patients in major prostate cancer study are more likely to die than real-world patients
April 25, 2018 - HBP researchers develop new tool to examine role of genes in disease-relevant brain regions
April 25, 2018 - Trio’s pioneering silicone ostomy product wins prestigious Queen’s Award for Enterprise
April 25, 2018 - Study highlights potential of stem cells derived from adults in regenerative medicine
April 25, 2018 - A new, emerging procedure burns cancer cells
April 25, 2018 - Acclarent introduces real-time, 3D navigation system for ENT procedures
April 25, 2018 - Italy’s prestigious Veneto Institute of Oncology acquires MILabs’ latest VECTor5CT system
April 25, 2018 - Future screening is more likely for people with false-positive cancer screening results
April 25, 2018 - Tweezers made of laser beams manipulate atoms to make new molecules
April 25, 2018 - Elevated immune function during childhood linked to stunted growth
April 25, 2018 - FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
April 25, 2018 - Research reveals autism and schizophrenia share common traits
April 25, 2018 - Perceived stress decreases for most women over 15-year span, study finds
April 25, 2018 - Coastal Genomics’ LightBench integrated with Hamilton liquid handler systems to bring efficiencies, savings for clinical laboratories
April 25, 2018 - Researchers discover new gene associated with aortic aneurysms
April 25, 2018 - Preantral zinc deficiency may affect fertility months
Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

image_pdfDownload PDFimage_print

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported today in the New England Journal of Medicine.

The international study, led by MSK medical oncologist and world-renowned kidney cancer expert Robert Motzer, MD, compared the combination of the two immunotherapies against sunitinib alone in people with advanced renal cell carcinoma (RCC) who had not yet received treatment. Researchers found that the combination of the immunotherapies ipilimumab and nivolumab extended overall survival, and objective response rates were significantly higher with the combination than with sunitinib alone.

“We have seen a significant improvement in overall survival,” said Dr. Motzer, lead author and principal investigator of the study. “This immunotherapy combination offers a completely different mechanism of action, and it introduces a new type of therapy in this setting. One earlier trial gave us a hint of potential, but this is the first time we have been able to demonstrate a survival benefit in a first-line therapy for renal cell carcinoma.”

In the randomized phase III trial, a total of 1,096 people who’d had no prior treatment were randomly assigned to treatment at 175 sites in 28 countries. There were 550 people treated with the nivolumab plus ipilimumab combination and 546 treated with sunitinib, the current standard of care. Researchers found a significant difference in overall survival favoring the ipilimumab and nivolumab combination, with an 18-month overall survival rate of 78 percent versus 68 percent with sunitinib alone.

This study was also designed for a formal statistical comparison between the sunitinib group and the combination group in producing objective responses (meaning substantial tumor shrinkage). Those receiving the combination also had a higher objective response. In addition, 9 percent of people in the combination trial had a complete response (with no evidence of the tumor remaining) versus 1 percent of those who received sunitinib alone.

Ipilimumab and nivolumab are part of a class of drugs called immune checkpoint inhibitors, which unleash the immune system to attack cancer. The immune system has several checkpoints in place to avoid an overreaction. Ipilimumab works by blocking the CTLA-4 checkpoint, a molecular brake that stops T cells from becoming fully and persistently activated. Similarly, nivolumab prevents the molecule PD-L1, expressed by tumors, from binding to T cells and deactivating them.

Because immunotherapy drugs work differently than targeted therapies, side effects can be significant.

Implications for People with RCC

Kidney cancer is notoriously difficult to treat. RCC, the most common form of the disease, is often diagnosed when it has already spread to other organs. Until recently, people with RCC had few therapeutic options. For years, oncologists have had very limited choices for how to treat people with metastatic RCC. The targeted therapy sunitinib was approved in 2006, based on studies led by Dr. Motzer at MSK. Since then, it has remained the standard of care as initial treatment for this disease.

More than 330,000 people are diagnosed with RCC every year, and the disease causes more than 140,000 deaths worldwide annually. It’s also particularly aggressive: At the time of diagnosis approximately 30 percent of people have metastatic disease, which means the cancer has already spread to other organs, and about one-third of people whose disease is confined to the kidney will relapse.

“This trial has produced practice-changing results in kidney cancer and represents another important step in the clinical trials program at MSK. We believe the results of this trial will now make this combination the standard of care in advanced metastatic kidney cancer,” said Dr. Motzer.

Immunotherapy at MSK

Cancer immunotherapy was born at MSK over a century ago. Since then, MSK scientists have led the effort to develop immune-based treatments for cancer. MSK has been at the epicenter of discoveries in the field, and the institution’s work is bringing exciting new treatment options to people with cancer.

The nivolumab and ipilimumab combination was developed at MSK by cancer immunologist Jedd Wolchok, MD, PhD. Positive results were found as a treatment for melanoma, and the combination now serves as the standard of care in that disease.

MSK has extensive experience in using immunotherapy to treat people with melanoma, kidney cancer, lung cancer, and others, as well as in handling immune-related side effects. On November 23, 2015, the Food and Drug Administration approved nivolumab for the treatment of advanced RCC. Although nivolumab was already used to treat melanoma and lung cancer, this marked the first time the FDA had approved a checkpoint inhibitor for the treatment of kidney cancer.​

Source:

https://www.mskcc.org/press-releases/pivotal-results-phase-iii-trial-show-combination-ipilimumab-and-nivolumab-increases-overall-survival-people-kidney

About author

Related Articles